Prevalence Of Dyslipidemia In Patients Research Articles

Lipid Profile Perturbations Associated With Subclinical Hypothyroidism: A Descriptive Study.

Background Hypothyroidism is a prevalent endocrine disorder associated with dyslipidemia, which increases cardiovascular risk. Our study aimed to estimate the prevalence of dyslipidemia and subclinical hypothyroidism (SCH) and their correlation in a diverse population. Methods A descriptive cross-sectional retrospective analysis was conducted to assess the prevalence of dyslipidemia in patients with SCH. Data were collected over 19 months from the Clinical Biochemistry Department of a Moroccan university hospital. A total of 447 patients were included based on comprehensive lipid profile andthyroid-stimulating hormone (TSH) assessments, and normal free thyroxine (FT4) levels. Lipid profile and TSHmeasurements followed standardized procedures using the Cobas Roche® 6000 system (Roche Diagnostics Corporation,Indianapolis,USA). Dyslipidemia and SCH were defined according to established thresholds recommended by reputable organizations. Statistical analyses were performed using SPSS version 23.0 (IBM Corp., Armonk, USA)and Microsoft Excel (Microsoft Corporation, Redmond, USA), with significance set at p <0.05. Results In the total population (447 individuals), the prevalence of dyslipidemia was approximately 42.05% (N = 188), with hypoHDLemia being most prevalent at approximately 31.31% (N = 140). The prevalence of SCHwas approximately 12.75% (N = 57), with women constituting approximately 7.6% and men approximately 5.15%. In the euthyroid group 1 (N = 390), the prevalence of dyslipidemia was approximately 40.76% (159 individuals), while in the hypothyroid group 2 (N = 57), it increased to approximately 50.87% (N = 29). Hypertriglyceridemia was more prevalent in Group 2, with a prevalence of approximately 21.05% (N = 12), compared to Group 1, which had a prevalence of approximately 13.84% (N = 54). Additionally, hypoHDLemia was notably higher in Group 2, with a prevalence of approximately 38.59% (N = 22), compared to Group 1, which had a prevalence of approximately 30.25% ( N = 118). The chi-square test revealed a significant association between SCH and dyslipidemia (χ2 = 1.427, p <0.05). The calculated odds ratio (OR) of 1.5 (p <0.05) indicates that individuals with SCHare 1.5 times more likely to have dyslipidemia compared to those without SCH. Conclusion In conclusion, our study provides valuable insights into the prevalence of dyslipidemia and its association with SCHin our patient population. We observed a notable prevalence of dyslipidemia among individuals with SCH, characterized by elevated levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C). Importantly, while chi-square tests revealed a significant association between SCH and dyslipidemia, logistic regression analyses did not confirm a statistically significant correlation after adjusting for potential confounders.

The impact of dyslipidemia on prognosis of patients after endovascular abdominal aortic aneurysm repair.

Dyslipidemia is common in patients with abdominal aortic aneurysm (AAA). However, there is insufficient research on the impact of dyslipidemia on the postoperative outcomes of patients with AAA after endovascular aortic aneurysm repair (EVAR). This study aimed to determine the impact of dyslipidemia on the prognosis of patients with AAA treated with EVAR. We retrospectively reviewed patients with AAA who underwent EVAR at our hospital between 2010 and 2020. The baseline characteristics and prognoses of patients in the dyslipidemia and non-dyslipidemia groups were analyzed. A total of 641 patients were included; the prevalence of dyslipidemia in patients with AAA was 42.3% (271/641), and the mean follow-up time was 63.37 ± 26.49 months. The prevalence of diabetes (10.0% vs. 15.1%, P = 0.050), peripheral arterial disease (17.3% vs. 25.8%, P = 0.018), and chronic kidney disease (3.0% vs. 6.3%, P = 0.043) was higher in the dyslipidemia group. The three-year all-cause mortality rate after EVAR was 9.98% (64/641), and there was no difference in the incidence of all-cause mortality (10.27% vs. 9.59%, P = 0.778) between the two groups. A total of 36 (5.62%) major adverse cardiovascular and cerebrovascular events (MACCEs) were observed within 3 years and were more common in patients with dyslipidemia (2.97% vs. 9.59%, P < 0.001). The incidence of stent-related complications in all patients was 19.97% (128/641), and there was no difference in the incidence of stent-related complications between the two groups (22.16% vs. 16.97%, P = 0.105); however, the incidence of type I endoleak in the dyslipidemia group was lower than that in the non-dyslipidemia group (9.19% vs. 4.06%, P = 0.012). Cox-regression analysis showed that high level of high-density lipoprotein cholesterol (HDL-C) was the protective factor (HR, 0.203, 95% CI, 0.067-0.616, P = 0.005) for MACCES, but it was the risk factor for type I endoleak (HR, 2.317, 95% CI, 1.202-4.466, P = 0.012). Dyslipidemia did not affect the mortality of patients with AAA who underwent EVAR; however, it may increase the incidence of MACCEs. Dyslipidemia may decrease the incidence of type I endoleaks after EVAR; however, further studies are warranted. We should strengthen the postoperative management of patients with dyslipidemia, prevent the occurrence of MACCEs.

Impact of diabetes mellitus on the frequency of post-operative complications after carotid endarterectomy.

There is significant controversy surrounding the link between diabetes mellitus and post-operative complications after carotid endarterectomy (CEA). The aim of this study was to identify the possible effects of diabetes on the frequency of post-operative complications after CEA. This prospective study was conducted at the Dedinje Clinic for Vascular Surgery, Belgrade. The patients who underwent CEA were divided into two groups: group A (37.7%) included 98 (35.1%) insulin-dependent and 181 (64.9%) insulin-independent diabetic patients, and group B (62.3%) comprised non-diabetic subjects. The pre-operative characteristics were similar, except for a greater prevalence of dyslipidaemia in patients with diabetes. Post-operative cardiac events occurred more often in patients with diabetes (3.6%) than in non-diabetic patients (1.1%) (p = 0.039); post-operative neurological events among patients with diabetes were 3.6% and among non-diabetics, 0.9% (p = 0.009). Peri-operative mortality rate was 2.5% in the diabetic group and 0.9% in the non-diabetic group. The total percentage of post-operative complications was two or more times higher in the diabetic group than the non-diabetic group (8.5 vs 18.3%, p < 0.001). Diabetes mellitus increased the surgical risk of CEA. Higher rates of mortality and post-operative complications were observed in patients being treated with oral antidiabetics than in those on insulin.

Decreasing trend of blood lipid profile in type 2 diabetes: Not a promising change in HDL-C, a serial cross-sectional study.

The prevalence of dyslipidemia in patients with type 2 diabetes (T2D) has been reported to be relatively high. The current study aimed to investigate the trend of serum lipid levels and the prevalence of dyslipidemia in patients with T2D. Data were extracted from a cohort of patients with T2D who had regular follow-ups every year for three years. TG, TC, LDL-C, HDL-C, and non-HDL-C were analyzed. The atherogenic index of plasma (AIP) was calculated using log (TG/HDL-C). A total of 747 patients with T2D were included in this study, consisting of 469 (62.8%) women and 278 (37.2%) men. There was a significant downward trend in mean TG, TC, LDL-C, non-HDL-C, and AIP levels. The trend of mean HDL-C levels showed no significant change. The prevalence of high TG, high TC, high LDL-C, and high non-HDL-C significantly decreased from the first to the last visit. There was no significant change in the trend of prevalence of low HDL-C. The prevalence of high AIP significantly decreased in women and showed no significant changes in men. A decreasing trend was observed in the mean levels and prevalence of TG, TC, LDL-C, non-HDL-C, and AIP. HDL-C did not change significantly. The success rate in achieving a complete normal lipid profile during follow-up years was not promising and continues to be challenging.

The prevalence of dyslipidemia in patients on hemodialysis: a cross-sectional study from Syria.

One hundred fifty-three HD patients were enroled in this retrospective cross-sectional study from two HD centres in Syria, from March 2021 to March 2022. Dyslipidemia is considered as follows; hyper-total cholesterol (TC) (≥200mg/dl), hyper-triglycerides (TG), (≥150mg/dl), hyper-low-density lipoprotein (LDL) (≥100mg/dl), hypo-high-density lipoprotein (HDL) (<40mg/dl), hyper-Non-HDL (≥130mg/dl). The most prevalent dyslipidemic parameter was low HDL (72.50%) followed by increased TGs (37.30%). TC, LDL, HDL, and Non-HDL showed differences between males and females (P=0.001, 0.015, 0.024, and 0.025; respectively). These parameters were higher in females. History of CVD showed associations with TC, LDL, HDL, and non-HDL (P=0.003, 0.007, 0.004, and 0.004; respectively). Additionally, statins showed effects on TC, LDL, and non-HDL (P=0.003, 0.0002, and 0.002; respectively); however, no relation with TG and HDL (P=0.9 and 0.4). HDL level showed differences in low (7.5%) and intermediate (10%) FRS (P=0.01 and 0.028; respectively); however, it did not show a difference in high (20%) FRS (P=0.68). The lipids profile did not show differences in different thresholds of atherosclerotic cardiovascular disease scores. The prevalence of dyslipidemia was high in HD patients in Syria. All lipid parameters except TG showed differences between males and females. Comparisons of lipid parameters with CVD risk stratifications support the need for further studies to prove the benefits of these scores in CVD prediction among the dialysis population.

Prevalence of dyslipidemia and the relationship between HbA1C and lipid profile in Moroccan patients with T2DM: a cross-sectional study.

the increased prevalence of dyslipidemia in patients with type 2 diabetes mellitus (T2DM) results from uncontrolled hyperglycemia and consistently contributes to an elevated risk of cardiovascular complications. This study sought to estimate the prevalence of dyslipidemia and to investigate the relationship between glycated hemoglobin (HbA1C) and serum lipid levels in Moroccan patients with T2DM. a total of 505 patients with T2DM were included in this cross-sectional study, 77.4% with chronic complications and 22.6% without. The collected data were examined using statistical package for the social sciences (SPSS) version 20.0 software and appropriate statistical methods. the data analysis showed that the mean and SD of age were 57.27±10.74 years. Among 505 patients with T2DM, the prevalence of hypercholesterolemia, hypertriglyceridemia, increased low-density lipoprotein cholesterol (LDL-C), and decreased HDL-C was 41.4%, 35.9%, 27.1%, and 17%, respectively. In addition, the data analysis showed that levels of total cholesterol (TC) (p≤0.001), triglycerides (p≤0.001), Low-density lipoprotein cholesterol (LDL-C) (p≤0.001), TC/HDL-C ratio (p=0.006), and LDL-C/HDL-C ratio (p=0.006) were significantly higher in T2DM patients with complications as compared to those without complications. The patients with HbA1C > 7.0% had significantly higher values of fasting blood glucose (FBG) (p≤0.001), total cholesterol (p≤0.001), triglycerides (p≤0.001), and TC/HDL-C ratio (p=0.025) as compared to the patients with HbA1C ≤ 7.0%. The HbA1C demonstrated a significant negative correlation with age (r=-0.139), and positive correlation with FBG (r=0.673), total cholesterol (r=0.189) and triglycerides (r=0.243). our results showed that HbA1C is the most important biomarker of long-term glycemic control and can also be a good indicator of the lipid profile.

Prevalence trends and related factors of hypertension patients complicating with dyslipidemia in community of Guandong province between 2013 and 2018

Objective: To analyze the prevalence trends and related factors of hypertension patients complicating with dyslipidemia in community. Methods: This was a cross-sectional survey, patients with hypertension were selected from the different communities of Guangdong province in 2013 and 2018 respectively. General clinical characteristics, including demographic information, past history, family history, and medication history, were collected. Dyslipidemia was defined as follows: at least 1 item elevation of total cholesterol (TC)≥5.2 mmol/L, triglyceride (TG) ≥1.7 mmol/L, low-density lipoprotein cholesterol (LDL-C)≥3.4 mmol/L, or reduced high-density lipoprotein cholesterol (HDL-C)<1.0 mmol/L. The incidence of dyslipidemia was standardized based on the 2010 China Census data, and further subgroup analysis was performed according to age (<50, 50-60, ≥60 years old) and sex (male, female). Multivariate logistic regression was used to analyze the related factors of dyslipidemia. Results: In 2013 and 2018, 7 866 (4 148 (52.7%) females, with the age of (62.4±13.6) years) and 11 611 (6 692 (57.6%) females, with the age of (58.2±9.3)years) patients with hypertension were enrolled for data analysis, respectively. In 2013, the total prevalence rate of dyslipidemia in patients with hypertension in the community of Guangdong province was 56.3%, among which the prevalence rates of hypercholesterolemia, hypertriglyceridemia, high LDL-Cemia, and low HDL-Cemia were 17.1. %, 21.3%, 2.3% and 24.4%, respectively. The total prevalence of dyslipidemia in patients with hypertension in the community of Guangdong in 2018 was 47.3%, prevalence of hypercholesterolemia, hypertriglyceridemia, high LDL-Cemia and low HDL-Cemia was 14.1%, 20.3%, 12.0% and 19.4%, respectively. Subgroup analysis showed that the total prevalence of dyslipidemia in male patients with hypertension in the community of Guangdong in 2013 and 2018 was 59.0% and 50.7%, respectively, among which hypercholesterolemia was 13.8% and 8.0%, and hypertriglyceridemia was 22.3%, 20.9%, high LDL-Cemia was 1.7%, 8.1%, low HDL-Cemia was 32.9%, 30.3%, respectively. In 2013 and 2018, the total prevalence of dyslipidemia in female patients with hypertension in the community of Guangdong province was 53.9% and 44.8%, among which prevalence of hypercholesterolemia was 20.5% and 18.5%, hypertriglyceridemia was 20.4% and 19.8%, and high LDL-Cemia was 2.7% and 14.9%, and hypo-HDL-Cemia was 16.8% and 11.3%, respectively. Age subgroup analysis showed that the prevalence of dyslipidemia among hypertensive patients aged<50, 50-60, and ≥60 years in Guangdong community in 2013 were 60.1%, 60.6%, and 53.7%, respectively; and 46.2%, 49.3% and 46.5% in 2018, respectively. Multivariate logistic regression analysis showed that women (OR=0.860,95%CI 0.761-0.973,P=0.017), obese (OR=2.295,95%CI 2.007-2.624,P<0.001), diabetes (OR=1.314,95%CI 1.090-1.583,P=0.004), stroke (OR=1.894,95%CI 1.227-2.924,P=0.004) and the level of fasting blood glucose (OR=1.105,95%CI 1.066-1.146,P<0.001) were independently related with the occurrence of dyslipidemia. Conclusions: The prevalence of dyslipidemia in patients with hypertension in the communities of Guangdong province is relatively high, and the prevalence differs in sex and age. Between 2013 and 2018, the total prevalence of dyslipidemia, hyper-TCemia, and hypo-HDL-Cemia in hypertensive patients shows a downward trend. The prevalence of hyper-TGemia remains unchanged, but the prevalence of high LDL-C shows an upward trend. Several factors are related to the prevalence of dislipidemia in hypertension patients in Guandong community.

DYSLIPIDEMIA IN TREATED AND UNTREATED PATIENTS WITH HYPERTENSION, DIABETES OR BOTH

Abstract Objective: We investigated the prevalence of dyslipidemia in patients with hypertension and diabetes mellitus alone or both and the association between dyslipidemia and the use of antihypertensive and antidiabetic agents. Methods: Our study participants were treated and untreated hypertensive and diabetic patients enrolled in a China nationwide registry. Dyslipidemia was defined as a serum concentration of triglycerides ?2.3 mmol/L, total cholesterol ?6.2 mmol/L, low-density lipoprotein (LDL) cholesterol ?4.1 mmol/L and high-density lipoprotein (HDL) cholesterol ?1.00 mmol/L. Design and method: Serum triglycerides and HDL cholesterol, but not total and LDL cholesterol were significantly different between patients with hypertension alone (n = 860), diabetes alone (n = 473) or both (n = 1090). The prevalence of dyslipidemia was not significantly different between patients with hypertension and diabetes or both for either component or overall (P = 0.34), except that in the subgroup younger than 50 years of age. It was higher in patients with hypertension and diabetes than those with either disease alone. However, treated, compared with untreated hypertensive patients had significantly lower serum total, LDL and HDL cholesterol, and similar serum triglycerides. And treated, compared with untreated diabetic patients had significantly lower serum triglycerides, total and LDL cholesterol but similar HDL cholesterol. The result remained similar for various forms of dyslipidemia. After adjustment for confounding factors, the results were confirmatory, with a significantly odds ratio of 0.76 (95% CI 0.58 - 0.997, P = 0.048) for hypercholesterolemia and 1.56 (95% CI 1.19 - 2.03, P = 0.001) for low HDL cholesterol associated with antihypertensive treatment, and of 1.50 (95% CI 1.18 - 1.89, P = 0.0008) for low HDL cholesterol associated with antidiabetic treatment. Further analyses showed that the odds for low HDL cholesterol was significantly (P?0.02) higher with the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (n = 927), diuretics/?-blockers (n = 547) and insulin (n = 460). Results: The prevalence of dyslipidemia was only sightly different between patients with hypertension and diabetes mellitus alone or both, but differed significantly between treated and untreated hypertension and diabetes in favour of treatment in spite of some compromise in HDL cholesterol with the use of some of medications.

A Cross-sectional Study to Estimate the Prevalence of Dyslipidaemia in Patients with Cholelithiasis

Introduction: Gallstones are one among the common gastrointestinal illness requiring hospitalisation and frequently occur in middle- aged otherwise healthy people with a prevalence of 10 to 15%. Women are more frequently affected than men. Most patients remain asymptomatic from their gallstones and remain silent throughout life. One major factor contributing to cholesterol stone formation is high concentration of cholesterol and lipids in bile secretion from liver. Changes in human behaviour and lifestyle over the last few decades have resulted in a dramatic increase in the incidence of dyslipidaemia and gallstone disease worldwide. Aim: To estimate the prevalence of dyslipidaemia in patients with gallstones. Materials and Methods: A cross-sectional study was done on 82 patients who were admitted in a tertiary care centre with gall stone confirmed by ultrasound abdomen, during the period between November 2016 to October 2017. Patients with dyslipidaemia taking medicine were excluded. Data were entered in structured data sheet which includes all the variables and results were expressed in frequency and percentage. Results: Forty-two patients were found to have dyslipidaemia and the prevalence was found to be 51.2%. Maximum prevalence of cholelithiasis was found in the 41-50 years age group (58.5%). Fifty-six were females (68.3%). Twenty-four patients had very high Serum Low Density Lipoprotiens (LDL) levels. Twenty-three had high levels of Triglycerides (TG) (28%). Six had very low High Density Lipoprotein (HDL) level (7.3%). Conclusion: The prevalence of dyslipidaemia estimated was 51.2%. Of the fractions of serum lipids, the LDL and triglycerides level elevations was more commonly detected in patients with gall stone.

Prevalence of Dyslipidemia in Patients with Acute Coronary Syndrome Admitted at Tertiary Care Hospital in Nepal: A Descriptive Cross-sectional Study.

Dyslipidemia is one of the major risk factors for acute coronary syndrome. Dyslipidemia with an increase in total cholesterol, low-density lipoprotein cholesterol, triglycerides and decrease in high-density lipoprotein cholesterol is one of the major risk factors for the acute coronary syndrome and alone account for more than 50% of population attributable risk. This study was conducted to find out the prevalence of dyslipidemia. This descriptive cross-sectional study was conducted in 105 patients admitted at the tertiary care center with a diagnosis of acute coronary syndrome from July 2018 to March 2019 after approval from the institutional review committee (Ref no. 205/2018). Fasting serum lipid profile was obtained within 24 hours of hospitalization with the convenient sampling method. Data were analyzed with the help of the Statistical Package for Social Sciences version 20. Point estimation at 95% Confidence interval was calculated along with frequency and proportion for binary data. Out of 105 people, dyslipidemia was present in 51 (48.6%). The mean age of the participants was 59.19±12.69 years. The majority 81 (77.1%) were male. The mean total cholesterol, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol were 183.43±35.9 mg/dl, 140.59±46.83 mg/dl, 109.9±26.38 mg/dl and 41.17±4.78 mg/dl respectively. High total cholesterol and triglyceride were found in 34 (32.4%) each, low high-density lipoprotein in 31 (29.5%) and high low-density lipoprotein in 22 (21%). Dyslipidemia is a significant risk factor in patients with acute coronary syndrome and commonly associated with other risk factors. Careful attention to its management may help to reduce further events.

Prevalence of Dyslipidemia in Patients with Type 1 Diabetes

Introduction: Patients with Type 1 Diabetes tend to present premature cardiovascular disease and dyslipidemia is a relevant risk factor in this cases. Objective: To determine the prevalence of dyslipidemia and its association with glycemic control, insulin therapy, nutritional therapy of carbohydrate counting, body mass index and physical activity level in children, adolescents and adults with Type 1 diabetes. Methodology: Cross-sectional study with 87 children, adolescents and adults with Type 1 Diabetes assisted in a public hospital in Brazil. The variables studied were: age, sex, education level, blood lipid levels, glycated hemoglobin, fasting glucose, body mass index, physical activity level, insulin therapy, and the nutrition therapy of carbohydrate counting. Data were collected from medical records and analyzed in their distribution, frequency, and association with the Person’s exct chi-squared test and Fisher’s exact test (p&lt;0,05). Results: The patients of the study were mostly adults (54%), females (64%) and, 40% concluded high school. The predominant insulin therapy was based in multiple daily injections with basal and rapid-acting analogs of insulin. The minority followed the nutrition therapy of carbohydrate counting. The prevalence of elevated glycated hemoglobin and fasting glucose was high (80,5% and 73,3%, respectively). Obesity was observed in 4,6% of adults. Regarding the blood lipid levels, hypercholesterolemia and low levels of HDL-c were observed in all age categories. Dyslipidemia was not associated with the variables of the study. Conclusion: There was observed dyslipidemia in all age categories of the patients of the study. Most of them were not following the nutrition therapy of carbohydrate counting and presented poor glycemic control. These two last caracteristics are modifiable and more educational activities should be developed to encourage self-care and prevent premature diabetes complications like cardiovascular diseases.

Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease.

SummaryBackgroundLiver disease impacts on hepatic synthesis of lipoproteins and lipogenesis but data on dyslipidemia during disease progression are limited. We assessed the patterns of dyslipidemia in (i) different liver disease etiologies and discriminated (ii) non-advanced (non-ACLD) from advanced chronic liver disease (ACLD) as it is unclear how progression to ACLD impacts on dyslipidemia-associated cardiovascular risk.MethodsPatients with alcoholic liver disease (n = 121), hepatitis C (n = 1438), hepatitis B (n = 384), metabolic/fatty liver disease (n = 532), cholestatic liver disease (n = 119), and autoimmune hepatitis (n = 114) were included. Liver stiffness ≥15 kPa defined ACLD. Dyslipidemia was defined as total cholesterol >200 mg/dL, low-density lipoprotein (LDL)-cholesterol >130 mg/dL and triglycerides >200 mg/dL.ResultsAcross all etiologies, total cholesterol levels were significantly lower in ACLD, when compared to non-ACLD. Accordingly, LDL-cholesterol levels were significantly lower in ACLD due to hepatitis C, hepatitis B, metabolic/fatty liver disease and autoimmune hepatitis. Triglyceride levels did not differ due to disease severity in any etiology. Despite lower total and LDL cholesterol levels in ACLD, etiology-specific dyslipidemia patterns remained similar to non-ACLD. Contrary to this “improved” lipid status in ACLD, cardiovascular comorbidities were more prevalent in ACLD: arterial hypertension was present in 26.6% of non-ACLD and in 55.4% of ACLD patients (p < 0.001), and diabetes was present in 8.1% of non-ACLD and 25.6% of ACLD patients (p < 0.001).ConclusionLiver disease etiology is a major determinant of dyslipidemia patterns and prevalence. Progression to ACLD “improves” serum lipid levels while arterial hypertension and diabetes mellitus are more prevalent. Future studies should evaluate cardiovascular events after ACLD-induced “improvement” of dyslipidemia.Electronic supplementary materialThe online version of this article (10.1007/s00508-019-01544-5) contains supplementary material, which is available to authorized users.

Prevalence of dyslipidemia in patients with type 2 diabetes mellitus: a cross sectional study

Prevalence of dyslipidemia in patients with type 2 diabetes mellitus: a cross sectional study

Dyslipidemia Prevalence among Tinnitus Patients of a Referral ENT Clinic in Tehran, Iran, 2018

Background: Tinnitus is a common neurosensory disorder that can bring many problems such as stress and sleep disorders to the patients and affect their quality of life. Unfortunately, its pathophysiology has not been exactly discovered yet, but there have been some studies executed about the possibility of dyslipidemia causing tinnitus. Studying more on this subject and especially on the Iranian population in order to provide us with evidence-based information, can help us find the optimal method to control and treat this disorder. Methods: In this study, 76 patients that have had complaints of tinnitus in the ENT (ears, nose, and throat) clinic of Taleghani hospital, Shahid Beheshti University of Medical Sciences, in the year 2018, were selected. Also, after taking a history about the severity and the onset of their problem, they were examined and also blood samples were taken to check their lipid profiles. Finally, the results of the lab tests, the severity and the onset of their disorder and also their age and sex were statistically analyzed. Results: The study showed that the prevalence of dyslipidemia in patients with tinnitus is not significantly greater than its prevalence in the general population. Furthermore despite the relationship between dyslipidemia and the onset and severity of the tinnitus is not significant, the effect of dyslipidemia on tinnitus shows itself after about one year and a half (P=0.000), it means dyslipidemia does not cause the tinnitus but affects in its duration. It also indicated the most common type of dyslipidemia among the patients that we studied, was Hypercholesterolemia with the prevalence of 23.68%. Conclusion: The Study suggests that despite the Hypercholesterolemia prevalence of 23.68% among these patients, dyslipidemia does not have a significant relationship with the severity of the neurosensory disorder "tinnitus’ overall, but dyslipidemia affects tinnitus after suffering for about one year and a half. Therefore there will not be a need to use blood tests in order to measure the lipid profile factors at the beginning and the first months of the patients’ tinnitus.

Prevalence of dyslipidemia and factors affecting lipid profile in patients with type 2 diabetes

AimDyslipidemia is an established marker for endothelial dysfunction and cardiovascular risk in diabetes. So we aimed to explore the prevalence of dyslipidemia in patients with type2 diabetes mellitus (DM) and to determine the association between dyslipidemia and other health care and biochemical indicators. Materials and methodsA cross-sectional study was carried out at private health care center. A total of 291 diabetic patients aged 18 years and above attended the clinic from August 2017 through April 2018 were included. Socio-demographic, clinical, and laboratory data were obtained from the medical records of patients. Statistical analysis was carried out using (SPSS, version 23). Resultsout of the 291 diabetes patients recruited 22.3% had hypercholesterolemia (TC ≥ 200) and 61.9% had hypertriglyceridemia. Abnormal LDL-C levels (≥130) were found in 8.9% of patients and HDL-C was less than 40 mg/dl in 54.3%. There was a statistically significant difference (P = 0.048) in abnormal HDL levels (˂ 40 mg/dl) among females (59.3%) and males (47.6). Patients with HbA1c values ≥ 7.0%had significantly higher values of total cholesterol (TC) and abnormal LDL-C compared with the patients who had HbA1c ˂ 7.0%. Conclusiondyslipidemia is highly prevalent among diabetic population particularly in those with poorly controlled diabetes. This calls for early and universal screening of lipid profile. There is also an urgent demand for measures that target tight glycemic, optimal lipid profile control and life style modifications is also required to all diabetic patients to achieve target value of HbA1C ≤ 7.

Current status of blood lipids in people with hypertension and diabetes in Henan province

Objective: To investigate the blood lipid levels and prevalence of dyslipidemia in people with hypertension and diabetes in Henan province. Methods: From April 2016 to April 2017, multi-stage cluster sampling was adopted to investigate 71 285 local residents aged between 35 and 75 from 6 districts and counties in Henan province including Zhongmu county of Zhengzhou city, Huojia county of Xinxiang city, Hualong district of Puyang city, Qi county of Hebi city, Xigong district of Luoyang city, and Wugang city of Pingdingshan city. Blood samples were collected. According to the diagnostic criteria of hypertension and diabetes, the study population was divided into control group (n=29 427), hypertension group (n=21 965), diabetes group (n=8 009) and hypertension-diabetes group (n=11 884). Comparisons on blood lipid levels and dyslipidemia between 4 groups were performed. Results: The total cholesterol (TC) level of all subjects was 4.37 (3.78, 5.05) mmol/L. The triglyceride (TG) level was 1.27 (0.97, 1.80) mmol/L, the low-density lipoprotein cholesterol (LDL-C) level was 2.34 (1.88, 2.88) mmol/L and the high-density lipoprotein cholesterol (HDL-C) level was 1.31 (1.08, 1.59) mmol/L. Except for the TC level in women aged 65-75 years and LDL-C levels in women aged 55-64 and 65-75 years, there were significant differences in TC, TG, LDL-C and HDL-C levels between subjects of control group, hypertension group, diabetes group, and hypertension-diabetes group in different age ranges (including 35-44, 45-54, 55-64,and 65-75 years) and genders(all P<0.01).Except for the LDL-C and HDL-C in men aged 35-44 years and LDL-C in women aged 65-75 years, there were significant differences in the dyslipidemia rates of TC, TG, LDL-C and HDL-C between subjects of control group, hypertension group, diabetes group and hypertension-diabetes group in different age ranges and genders(P<0.01 or <0.05). After adjusting for age, gender, smoking, drinking, snoring, region, and body mass index, multivariate logistic regression analysis showed that hypertension (OR=1.221, 95%CI 1.113-1.339, P<0.01), diabetes (OR=1.636, 95%CI 1.461-1.833, P<0.01) and hypertension-diabetes (OR=1.832, 95%CI 1.658-2.023, P<0.01) were independent risk factors for TC abnormality. Hypertension (OR=1.566, 95%CI 1.478-1.659, P<0.01), diabetes (OR=2.182, 95%CI 2.031-2.342, P<0.01) and hypertension-diabetes (OR=2.655, 95%CI 2.492-2.829, P<0.01) were also independent risk factors for TG abnormality. Diabetes (OR=1.510, 95%CI 1.309-1.742, P<0.01) and hypertension-diabetes (OR=1.461, 95%CI 1.285-1.661, P<0.01) were independent risk factors for LDL-C abnormality. Diabetes (OR=1.261, 95%CI 1.180-1.346, P<0.01) and hypertension-diabetes (OR=1.195, 95%CI 1.126-1.268, P<0.01) were independent risk factors for HDL-C abnormality. Conclusion: The prevalence of dyslipidemia in patients with hypertension and diabetes is high in Henan province, so adequate blood lipid education and control should be applied to people with risk factors as soon as possible.

Association of HbA1c, serum uric acid and non HDL cholesterol in type 2 diabetes patients

Dyslipidemia is an established marker for endothelial dysfunction and cardiovascular risk in diabetes. So we aimed to explore the prevalence of dyslipidemia in patients with type2 diabetes mellitus (DM) and to determine the association between dyslipidemia and other health care and biochemical indicators.A cross-sectional study was carried out at private health care center. A total of 291 diabetic patients aged 18 years and above attended the clinic from August 2017 through April 2018 were included. Socio-demographic, clinical, and laboratory data were obtained from the medical records of patients. Statistical analysis was carried out using (SPSS, version 23).out of the 291 diabetes patients recruited 22.3% had hypercholesterolemia (TC ≥ 200) and 61.9% had hypertriglyceridemia. Abnormal LDL-C levels (≥130) were found in 8.9% of patients and HDL-C was less than 40 mg/dl in 54.3%. There was a statistically significant difference (P = 0.048) in abnormal HDL levels (˂ 40 mg/dl) among females (59.3%) and males (47.6). Patients with HbA1c values ≥ 7.0%had significantly higher values of total cholesterol (TC) and abnormal LDL-C compared with the patients who had HbA1c ˂ 7.0%.dyslipidemia is highly prevalent among diabetic population particularly in those with poorly controlled diabetes. This calls for early and universal screening of lipid profile. There is also an urgent demand for measures that target tight glycemic, optimal lipid profile control and life style modifications is also required to all diabetic patients to achieve target value of HbA1C ≤ 7.

Dyslipidemia in People Living with HIV on Anti-Retroviral Treatment: Case of the Ambulatory Treatment Center (ATC) of the Sylvanus Olympio University Hospital of Lome

Introduction: Dyslipidemia is a significant cardiovascular risk factor in patients living with HIV (PLWHIV). Few data are available in Togo. Objective: The purpose of this study is to assess the prevalence of dyslipidemia and associated factors in PLWHIV on Highly Active Antiretroviral Therapy (HAART). Methods: This is a descriptive and analytical cross-sectional study of patients followed at the Sylvanus Olympio University Hospital’s infectious diseases department for six months. The study population consisted of any PLWHIV patient on HAART over 18 years of age who had been regularly monitored and had a serum lipid fraction assay. Results: Two hundred and eighty-four patients were included. 75.4% were women. The median age was 46 years (IQR: 39 - 52) and the median CD4 count was 461 cel/U1 (IQR: 330 - 607). Eighty-three percent of the patients had suppressed viral load. The median duration of follow-up under antiretroviral treatment antiretroviral treatment was 4.18 years (IQR: 2 - 7). The prevalence of dyslipidemia was 72.5%. HDL hypocholesterolemia (HDL-c < 40 mg/dl) was the most represented dyslipidemia in 49.6%. Body mass index, past treated tuberculosis, HAART regimen substitution, abdominal obesity, past smoking and being exposed to Nucleoside reverse transcriptase inhibitors (NRITs) were found to be factors associated to dyslipidemia. Conclusion: Our study revealed a high prevalence of dyslipidemia in patients on HAART as well as associated factors. To this end, it is necessary to insist on screening for dyslipidemia before and after initiation of HAART in order to prevent the occurrence of cardiovascular events in PLWHIV.

Safety of statin drugs in patients with dyslipidemia and stable systemic autoimmune myopathies.

Recent studies have shown a high prevalence of dyslipidemia in patients with systemic autoimmune myopathies (SAM). However, little is known about the safety of the use of statins in these patients, and this gap in research motivated the accomplishment of the present study. In a retrospective cohort study conducted from 2004 to 2018, 250 patients with SAM were evaluated, and 24 patients had stable forms of SAM (16 dermatomyositis, 1 polymyositis and 7 antisynthetase syndrome) but had dyslipidemia and had received statins. Patients with clinically amyopathic dermatomyositis, immune-mediated necrotizing myopathy, dermatomyositis, or polymyositis induced by statins were excluded. The mean age of the patients was 50.6years, and they were predominantly women. The median duration of the disease was 5.0years. Twelve patients received simvastatin (10-60mg/day), and 11 patients received atorvastatin (20-40mg/day), and 1 patient received atorvastatin (10mg/day) which was later replaced by simvastatin (20mg/day). The median time of exposure to the statin was 22.5months. The follow-up appointments showed that the patients' lipid profiles had improved and that there had been no recurrences of disease activity or clinical intercurrences. Despite the small sampling, the data showed that the use of statins in patients with SAM was safe. New studies with a larger sample and patients with different degrees of disease activity are necessary to corroborate the results of the present study.

Dyslipidemia among Patients with End Stage Renal Disease on Maintenance Hemodialysis

Dyslipidemia has been suggested to be one of the factors that contribute to the high incidence of cardiovascular disease in hemodialysis patients. Previous studies suggest that end-stage renal disease may contribute to dyslipidemia. The aim of the study: to assess the prevalence of dyslipidemia in patients on maintenance hemodialysis. Patients and Methods: A case-control study was conducted from February 2015 until August 2015 in Ibn-Sena teaching hospital on 100 participants (52 males and 48 females), 50 were patients with end-stage renal disease on regular hemodialysis and 50 were age and gender-matched apparently healthy subjects as the control. Questioner used to collect data, a thorough examination was done including height and weight and BMI. A blood sample from all participants in fasting state was sent for the renal function test, complete blood picture, serum albumin, electrolytes, TG, total cholesterol, LDL and HDL measured by the enzymatic method, plasma atherogenic index calculated as [log (TG/HDL)]. Results: Age of the participants ranged between 18 - 70 years and the mean age was (44.45 ± 13.6) years. In HD group, the mean cholesterol was (3.29 + 0.73) mmol/l, serum TG (2.38 ± 0.56) mmol/l, LDL (1.91 ± 0.66) mmol/l, HDL (0.88 ± 0.2) mmol/l, atherogenic index (0.434 ± 0.16), while in control group, the mean cholesterol was (4.17 ± 0.69) mmol/l, serum TG (1.6 ± 0.43) mmol/l, LDL (2.69 ± 0.63 ) mmol/l, HDL (1.066 ± 0.13) mmol/l, atherogenic index (0.177 ± 0.12). The lipid abnormalities in hemodialysis group were high plasma atherogenic index in 84%, hypertriglyceridemia 50%, hypercholesterolemia 8% and high LDL 6% and low HDL in 48%, while in control group, high plasma atherogenic index in 34%, hypertriglyceridemia in 26%, hypercholesterolemia 14% high LDL 7% and low HDL in 16%. Conclusions: patients with end-stage renal disease on hemodialysis have significant dyslipidemia compared to control group characterized by hypertriglyceridemia, low HDL and high atherogenic index of plasma.